Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding Ltd (OP:RHHVF)

416.11 +15.78 (+3.94%)
Streaming Delayed Price Updated: 3:25 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Ltd

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial ↗
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... 
Via Benzinga
News headline image
Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests ↗
Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH 
Via Benzinga
News headline image
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues ↗
Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,  
Via Benzinga
News headline image
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab ↗
Biogen Inc (NASDAQ: BIIB) has  
Via Benzinga
News headline image
FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo ↗
The FDA has approved Genentech's, a unit of  
Via Benzinga
News headline image
Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months ↗
The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) supplemental marketing application for Evrysdi (... 
Via Benzinga
News headline image
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply ↗
The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild... 
Via Benzinga
News headline image
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases ↗
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)... 
Via Benzinga
News headline image
Novartis Launches New Share Buyback Program Of Up To $15B ↗
Novartis AG (NYSE: NVS) is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, adding it was confident in its top-line growth... 
Via Benzinga
News headline image
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape... 
Via Benzinga
News headline image
Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients ↗
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen... 
Via Benzinga
News headline image
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings ↗
Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60%... 
Via Benzinga
News headline image
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial ↗
Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS).... 
Via Benzinga
News headline image
Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer ↗
Roche Holdings AG (OTC: RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus... 
Via Benzinga
News headline image
Europe Approves Roche's Tocilizumab For Patients With Severe COVID-19 ↗
The European Commission has extended the marketing authorization for Roche Holdings AG's (OTC: RHHBY) Actemra/RoActemra (Tocilizumab) to treat patients with severe... 
Via Benzinga
News headline image
Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients ↗
Immunocore Holdings Plc (NASDAQ: IMCR) announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid... 
Via Benzinga
News headline image
Biden's New COVID-19 Plan Includes Reimbursement For Over The Counter, At-Home COVID Tests ↗
President Biden announced that private health insurance plans would soon reimburse people who buy over-the-counter (OTC), at-home rapid tests for COVID-19. What Happened... 
Via Benzinga
News headline image
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact ↗
Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY... 
Via Benzinga
News headline image
Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer ↗
The European Commission (EC) has granted conditional marketing authorization to Roche Holdings AG's (OTC: RHHBY) Gavreto (pralsetinib) for treating adults... 
Via Benzinga
News headline image
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
News headline image
Spark Therapeutics' Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes ↗
Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced data from its Phase 1/2 trial of SPK-8011 in hemophilia A. At a median efficacy follow-up of 33.4... 
Via Benzinga
News headline image
Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill ↗
Roche Holdings AG (OTC: RHHBY) has ended a partnership with Atea Pharmaceuticals Inc (NASDAQ: AVIR) to jointly develop a COVID-19 antiviral pill, a month... 
Via Benzinga
News headline image
Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail ↗
The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and... 
Via Benzinga
News headline image
EU Regulator Backs Regeneron-Roche's COVID-19 Drug ↗
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc... 
Via Benzinga
News headline image
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters ↗
With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition.... 
Via Benzinga
News headline image
ALX Oncology Falls After Updated Data For Solid Tumors Candidate ↗
ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/... 
Via Benzinga
News headline image
Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg... 
Via Benzinga
News headline image
Novartis To Offload Its Stake Back To Roche For $20.7B ↗
Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting... 
Via Benzinga
News headline image
Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting ↗
Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in... 
Via Benzinga
News headline image
Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics ↗
Roche Holding AG (OTC: RHHBY) raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, driven by demand for COVID-19 tests and the strong... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.